pharma · Waldenstrom Macroglobulinemia · Non Small Cell Lung Cancer · CLRB
Cellectar Biosciences
Cellectar Biosciences clinical programs — 17 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 100 Campus Dr, 207, Florham Park, New Jersey 07932, US
- Employees
- 21
- Programs
- 17
- Drugs
- 7
- Patents
- 7
Cellectar Biosciences projects
17 ClinicalTrials.gov programs sponsored by Cellectar Biosciences.
Cellectar Biosciences has 17 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Paclitaxel
Cellectar Biosciences
Non Small Cell Lung Cancer
1 trial -
I-124-CLR1404
Cellectar Biosciences
Glioblastoma
1 trial -
I-131-CLR1404 Injection
Cellectar Biosciences
Glioma
1 trial -
Iopofosine I 131 single dose
Cellectar Biosciences
Waldenstrom Macroglobulinemia
1 trial -
NOV-002
Cellectar Biosciences
Leukemia
1 trial -
NOV-002
Cellectar Biosciences
Ovarian Cancer
1 trial -
NOV-205
Cellectar Biosciences
Hepatitis C
2 trials -
POTASSIUM IODIDE
Cellectar Biosciences
Waldenstrom Macroglobulinemia
1 trial -
CLR 131
Cellectar Biosciences
Pediatric Solid Tumor
1 trial -
CLR 131
Cellectar Biosciences
Head and Neck Cancer
1 trial -
CLR 131
Cellectar Biosciences
High-Grade Glioma
1 trial -
I-131-CLR1404
Cellectar Biosciences
Solid Tumors
1 trial -
I-131-CLR1404
Cellectar Biosciences
Cancer
1 trial -
I-131-CLR1404
Cellectar Biosciences
Multiple Myeloma
1 trial -
I124-NM404
Cellectar Biosciences
Non Small Cell Lung Cancer
1 trial -
Iopofosine I 131
Cellectar Biosciences
Breast Cancer
1 trial -
RNL-Vascostem®
Cellectar Biosciences
Buerger's Disease
1 trial
Frequently asked questions
How many clinical projects does Cellectar Biosciences have?
17 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.